Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy

Summary

Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate treatment and evaluation of the epileptogenic zone or network. Iron deposition in cerebral cavernous malformations has been postulated to play an important role in triggering CRE. Quantitative susceptibility mapping (QSM), as an optimal in vivo imaging technique to quantify iron deposition, is employed to analyze the iron quantity in CCM patients with epilepsy and further combined with brain structural and connectome analysis, to describe the difference between CCMs with and without epilepsy. In vivo biomarkers predicting CRE risk in CCM natural history and CRE control outcome after CCM surgical resection will be further identified to improve management strategy.

Eligibility

Inclusion Criteria:

* (1) 18 to 70 years of age
* (2) Diagnosed with a single cerebral cavernous malformation
* (3) No prior treatment of the symptomatic lesion

Exclusion Criteria:

* (1) Associated with brain lesions and/or tumors other than CCM
* (2) History of previous intracranial surgery
* (3) Prior brain irradiation
* (4) Contraindication or unwilling or unable to undergo research MRI studies
* (5) Pregnant or breastfeeding women
* (6) Persons unable or unlikely to return for follow-up visits
* (7) Dementia or other progressive neurological disease

Conditions8

Browse More Trials